Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÀڱðæºÎ¾Ï¿¡ À־ ¹æ»ç¼±Ä¡·á ÈÄÀÇ Ä¡·á½ÇÆÐ ºÐ¼® Analysis of Treatment Failure after Curative Radiotherapy in Uterine Cervical Carcinoma

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2001³â 19±Ç 3È£ p.224 ~ 229
¼Ò¼Ó »ó¼¼Á¤º¸
ä±Ô¿µ/Gye Young Chai °­±â¹®/ÀÌÁ¾ÇÐ/Ki Mun Kang/Jong Hak Lee

Abstract

¸ñÀû: ¹æ»ç¼±´Üµ¶À¸·Î Ä¡·áÇß´ø ÀڱðæºÎ¾Ï¿¡¼­ Ä¡·á½ÇÆÐ ¾ç»ó°ú Ä¡·á½ÇÆп¡ ´ëÇÑ À§ÇèÀÎÀÚ¸¦ È®ÀÎÇÏ¿© µ¿½ÃÇ×¾ÏÈ­Çйæ»ç¼±¿ä¹ýÀÇ Àû¿ë±âÁØÀ» ¸¶·ÃÇÏ°íÀÚ º» ¿¬±¸¸¦ ½ÃÇàÇÏ¿´´Ù. ´ë»ó ¹× ¹æ¹ý: 1989³â 4¿ùºÎÅÍ 1997³â 12¿ù±îÁö °æ»ó´ëÇб³º´¿ø
Ä¡·á¹æ»ç¼±°ú¿¡¼­ ÀڱðæºÎ¾ÏÀ¸·Î ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇà¹ÞÀº ȯÀÚÁß ¿ÜºÎ¹æ»ç¼±Á¶»ç¿Í °­³»Á¶»ç¸¦ °èȹ´ë·Î ¿Ï·áÇÑ 154¸íÀ» ´ë»óÀ¸·Î ÈÄÇâÀû ºÐ¼®À» ½ÃÇàÇÏ¿´´Ù. FIGO¿¡ ÀÇÇÑ º´±âº° ºÐÆ÷´Â ¥°b 12¸í, ¥±a 24¸í, ¥±b 98¸í, ¥²a 1¸í, ¥²b 17¸í, ¥³a 2¸íÀ̾ú´Ù. »ýÁ¸À²Àº
Kaplan-Meyer ¹ýÀ» ÀÌ¿ëÇÏ¿© ±¸ÇÏ¿´°í, »ýÁ¸À²ÀÇ ºñ±³´Â Log-rank test·Î, ´Ùº¯·®ºÐ¼®Àº Cox proportional hazard modelÀ» ÀÌ¿ëÇÏ¿´´Ù. ±¹¼Ò ¶Ç´Â ¿ø°Ý½ÇÆп¡ ´ëÇÑ ´Üº¯·®, ´Ùº¯·®ºÐ¼®Àº logistic regression modelÀ» »ç¿ëÇÏ¿´´Ù. ¹æ±¤ ¹× Á÷ÀåÀÇ ÇÕº´Áõ Æò°¡´Â
RTOG/EORTC¿¡¼­ Á¦¾ÈÇÏ¿© »ç¿ëÇÏ°í ÀÖ´Â SOMA scaleÀ» Àû¿ëÇÏ¿´´Ù. °á°ú: Àüü 154¸í °¡¿îµ¥ ¿ÏÀü °üÇظ¦ º¸ÀÎ °æ¿ì´Â 130¸íÀ¸·Î ¿ÏÀü°üÇØÀ²Àº 84.4%¿´´Ù. ¿ÏÀü°üÇØÀÚ °¡¿îµ¥ 6¸íÀÌ ±¹¼ÒÀç¹ß, 25¸íÀÌ ¿ø°ÝÀüÀÌ, 10¸íÀÌ ±¹¼ÒÀç¹ß ¹× ¿ø°ÝÀüÀ̸¦ º¸¿©
¿ÏÀü°üÇØÀÚ
°¡¿îµ¥ 31.5%°¡ Ä¡·á¿¡ ½ÇÆÐÇÏ¿´´Ù. ¿¬±¸´ë»ó ÀüüÀÇ Ä¡·á½ÇÆоç»óÀ» º¸¸é ±¹¼Ò½ÇÆа¡ 25¸í, ¿ø°Ý½ÇÆа¡ 25¸í, ±¹¼Ò ¹× ¿ø°Ý½ÇÆа¡ 15¸íÀ¸·Î ÀüüȯÀÚÀÇ Ä¡·á½ÇÆÐÀ²Àº 42.1% (65/154)¿´°í, ±¹¼Ò½ÇÆÐÀ²(±¹¼Ò´Üµ¶½ÇÆÐ¿Í ±¹¼Ò, ¿ø°Ý ÀÌÁß½ÇÆи¦ ÇÕÇÑ °Í) ¹×
¿ø°Ý½ÇÆÐÀ²(¿ø°Ý´Üµ¶½ÇÆÐ¿Í ±¹¼Ò, ¿ø°Ý ÀÌÁß½ÇÆи¦ ÇÕÇÑ °Í)Àº °¢°¢ 25.9% (40/154), 25.9% (40/154)¿´´Ù. ±¹¼Ò½ÇÆÐÀÇ À§ÇèÀÎÀڷμ­´Â ´Üº¯·®, ´Ùº¯·®ºÐ¼® ¸ðµÎ¿¡¼­ Á¾¾çÀÇ Å©±â°¡ À¯ÀÇÇÏ¿´°í ¿ø°Ý½ÇÆÐÀÇ À§ÇèÀÎÀڷμ­´Â ´Üº¯·®ºÐ¼®¿¡¼­´Â º´¸®, Á¾¾çÀÇ Å©±â,
°ñ¹ÝÀÓÆÄÀýÀüÀÌ, Ä¡·áÀü Ç÷»ö¼Ò ¼öÄ¡°¡ À¯ÀÇÇÏ¿´À¸³ª, ´Ùº¯·®ºÐ¼®¿¡¼­´Â Á¾¾çÀÇ Å©±â, °ñ¹ÝÀÓÆÄÀýÀüÀÌ°¡ À¯ÀÇÇÏ¿´´Ù. 5³â »ýÁ¸À²Àº FIGO ¥°b 74%, ¥±a 67%, ¥±b 63%, ¥²b 45%¿´´Ù. °á·Ð: Á¾¾çÀÇ Å©±â°¡ 4 §¯ ÀÌ»óÀÎ °æ¿ì ¹æ»ç¼±Ä¡·á¸¸À¸·Î´Â ±¹¼Ò ¹×
¿ø°Ý½ÇÆÐÀÇ
°¡´É¼ºÀÌ ³ô°í »ýÁ¸À² ¿ª½Ã ³·´Ù. Å©±â°¡ 4 §¯ ÀÌ»óÀ̰ųª °ñ¹ÝÀÓÆÄÀýÀüÀÌ°¡ ÀÖ´Â °æ¿ì ´ëµ¿¸ÆÀÓÆÄÀý ÀüÀÌ °¡´É¼ºÀÌ ³ô´Ù. µû¶ó¼­ Å©±â°¡ 4 §¯ ÀÌ»óÀ̰ųª °ñ¹ÝÀÓÆÄÀý ÀüÀÌ°¡ ÀÖ´Â °æ¿ì ±¹¼ÒÁ¦¾îÀ²À» ³ôÀÌ°í ¿ø°ÝÀüÀ̸¦ ÁÙÀ̱â À§ÇØ µ¿½Ã¹æ»ç¼±Ç×¾ÏÈ­Çпä¹ýÀ»
½ÃÇàÇÏ¿©¾ß
ÇÑ´Ù.

Purpose: The aim of this study is to analyze the treatment failure patterns and the risk factors for locoregional or distant failure of uterine cervical carcinoma treated with radiation therapy. Materials and methods: A
retrospective
analysis was undertaken of 154 patients treated with curative radiation therapy in Gyeongsang National University Hospital from April 1989 through December 1997. According to FIGO classification, 12 patients were stage ¥°B, 24 were ¥±A, 98 were
¥±B, 1
were ¥²A, 17 were ¥²B, 2 were ¥³A. Results: Overall treatment failure rate was 42.1% (65/154), and that of complete responder was 31.5% (41/130). Among 65 failures, 25 failed locoregionally, another 25 failed distantly, and 15 failed
locoregionally and distantly. Multivariate analysis confirmed tumor size (>4 §¯) as risk factor for locoregional failure, and tumor size (>4 §¯), pelvic lymph node involvement as risk factors for distant failure. Conclusion: On the basis
of
results of our study and recent published data of prospective randomized study for locally advanced uterine cervical carcinoma, we concluded that uterine cervical carcinoma with size more than 4 §¯ or pelvic lymph node involvement should be
treated
with
concurrent chemoradiation.

Å°¿öµå

ÀڱðæºÎ¾Ï; ¹æ»ç¼±Ä¡·á; ½ÇÆоç»ó; Cervix cancer; Radiotherapy; Failure pattern;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS